Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. Read more on VIR stock here.
Vir hepatitis delta combo hit its phase 3 goal, with phase 2 showing lasting viral suppression.
Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.
Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.
This is the newest page. Registered accounts read further back.